Albert Dordal
Research Subjects
Albert Dordal has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Carmen Almansa
ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain
3 shared publications - José Luis Díaz
ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain
3 shared publications - Ana Montero
Drug Discovery and Preclinical Development, Esteve , Baldiri Reixach, 4-8 , 08028 Barcelona , Spain .; Tel: +0034934466000
2 shared publications Jordi Corbera
Drug Discovery and Preclinical Development, Esteve , Baldiri Reixach, 4-8 , 08028 Barcelona , Spain .; Tel: +0034934466000
2 shared publications- Sandra Yeste
WELAB, Parc Científic Barcelona C/Baldiri Reixac 4–8 08028 Barcelona Spain
2 shared publications - Ana Paz Marín
Drug Discovery and Preclinical Development , Esteve, Baldiri Reixach, 4-8 , 08028 Barcelona , Spain .; Tel: +34934466000
1 shared publication
Latest Publications
- 17 January 2024
- Published by Wiley in ChemMedChem
- Vol. 19 (10) , e202300473
Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Cavα2δ‐1 Subunit of Voltage‐Gated Calcium Channel and the μ‐Opioid Receptor
The synthesis and pharmacological activity of a new series of dual ligands combining activities towards the α2δ‐1 subunit of voltage‐gated calcium channels (Cavα2δ‐1) and the μ‐opioid receptor (MOR) as novel pain therapeutics are reported. A careful exploration of the pharmacophores related to both targets, which in principle had few common characteristics, led to the design of novel compounds exhibiting both activities. The construction of the dual ligands started from published Cavα2δ‐1 ligands, onto which MOR ligand pharmacophoric elements were added. This exercise led to new amino‐acidic substances with good affinities on both targets as well as good metabolic and physicochemical profiles and low potential for drug‐drug interactions. A representative compound, (2S,4S)‐4‐(4‐chloro‐3‐(((cis)‐4‐(dimethylamino)‐4‐phenylcyclohexyl)methyl)‐5‐fluorophenoxy)pyrrolidine‐2‐carboxylic acid, displayed promising analgesic activities in several in vivo pain models as well as a reduced side‐effect profile in relation to morphine.
- 17 January 2024
- Published by Wiley in ChemMedChem
- Vol. 19 (10) , e202300473
Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Cavα2δ‐1 Subunit of Voltage‐Gated Calcium Channel and the μ‐Opioid Receptor
The synthesis and pharmacological activity of a new series of dual ligands combining activities towards the α2δ‐1 subunit of voltage‐gated calcium channels (Cavα2δ‐1) and the μ‐opioid receptor (MOR) as novel pain therapeutics are reported. A careful exploration of the pharmacophores related to both targets, which in principle had few common characteristics, led to the design of novel compounds exhibiting both activities. The construction of the dual ligands started from published Cavα2δ‐1 ligands, onto which MOR ligand pharmacophoric elements were added. This exercise led to new amino‐acidic substances with good affinities on both targets as well as good metabolic and physicochemical profiles and low potential for drug‐drug interactions. A representative compound, (2S,4S)‐4‐(4‐chloro‐3‐(((cis)‐4‐(dimethylamino)‐4‐phenylcyclohexyl)methyl)‐5‐fluorophenoxy)pyrrolidine‐2‐carboxylic acid, displayed promising analgesic activities in several in vivo pain models as well as a reduced side‐effect profile in relation to morphine.
- 20 April 2017
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 8 (6) , 1246-1254
Pyrazolo[3,4-d]pyrimidines as sigma-1 receptor ligands for the treatment of pain. Part 2: Introduction of cyclic substituents in position 4
A SAR study identified the 4-(1-methylpyrazol-5-yl) derivative, 12f, as a selective σ1R antagonist with a good ADMET profile and potent antinociception.
- 20 April 2017
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 8 (6) , 1246-1254
Pyrazolo[3,4-d]pyrimidines as sigma-1 receptor ligands for the treatment of pain. Part 2: Introduction of cyclic substituents in position 4
A SAR study identified the 4-(1-methylpyrazol-5-yl) derivative, 12f, as a selective σ1R antagonist with a good ADMET profile and potent antinociception.
- 20 April 2017
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 8 (6) , 1235-1245
Pyrazolo[3,4-d]pyrimidines as sigma-1 receptor ligands for the treatment of pain. Part 1: 4-acylamino derivatives
The 4-acylaminopyrazolo[3,4-d]pyrimidine9awas identified as a highly selective σ1R antagonist, showing as well substantial antinociceptive properties.
- 20 April 2017
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 8 (6) , 1235-1245
Pyrazolo[3,4-d]pyrimidines as sigma-1 receptor ligands for the treatment of pain. Part 1: 4-acylamino derivatives
The 4-acylaminopyrazolo[3,4-d]pyrimidine9awas identified as a highly selective σ1R antagonist, showing as well substantial antinociceptive properties.